Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Trial in progress: A phase 3, multi-regional, open-label, randomized study of tirabrutinib vs rituximab and temozolomide in participants with Relapsed/Refractory primary central nervous system lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

CGChristian GrommesTBTracy T. Batchelor

Discussion

Loading...

Member takes

Overview

Randomized trial compares progression-free survival in patients with relapsed/refractory PCNSL, highlighting tirabrutinib's potential benefits.

Key Points

  • Overall response rate in prior studies shows the need for novel therapies in r/r PCNSL.
  • Randomized study evaluates tirabrutinib against combination therapy to improve patient outcomes.
  • Tumor response assessments will occur at key intervals during 28-day cycles for treatment monitoring.
  • Significant adverse events from current PCNSL treatments call for effective and safer options for patients.

Cite This Study

Grommes et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236dec6https://doi.org/10.1182/blood-2025-3703
View Full Paper
Ask AI
Bookmark
Share